Clinical Trial Update: A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating LGX818 in combination with MEK162 for BRAF V600-mutant solid tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors Harboring Braf V600 Mutation

Drugs mentioned

• LGX818 (encorafenib)
• MEK162 (binimetinib)

Snippet

Sponsor: Pfizer | Conditions: Solid Tumors Harboring a BRAF V600 Mutation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-03-13